Trial Profile
An Open-label, Multi-center, Phase 1/2 Study to Evaluate the Safety and Immunogenicity of an Intramuscular Injection of TAK-850 in Healthy Pediatric Subjects
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs TAK 850 (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Takeda
- 15 Jun 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 25 Feb 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov
- 24 Feb 2015 New trial record